iRadimed Corporation (NASDAQ:IRMD) Receives Average Recommendation of “Moderate Buy” from Analysts

iRadimed Corporation (NASDAQ:IRMD) has been assigned an average rating of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $120.00.

A number of analysts have weighed in on IRMD shares. Weiss Ratings cut iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

iRadimed Stock Performance

iRadimed stock opened at $86.95 on Monday. The stock has a market cap of $1.11 billion, a P/E ratio of 48.58 and a beta of 0.90. The company has a fifty day simple moving average of $94.17 and a 200-day simple moving average of $94.85. iRadimed has a 12-month low of $67.84 and a 12-month high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, sell-side analysts forecast that iRadimed will post 1.98 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, August 14th. iRadimed’s dividend payout ratio (DPR) is 44.69%.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. The trade was a 0.12% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 34.60% of the company’s stock.

Institutional Trading of iRadimed

Several hedge funds have recently made changes to their positions in the company. Man Group plc purchased a new stake in shares of iRadimed in the second quarter valued at about $1,514,000. Jupiter Topco LLC acquired a new stake in iRadimed in the second quarter valued at about $296,000. Hsbc Holdings PLC purchased a new stake in iRadimed in the 2nd quarter valued at approximately $1,130,000. PDT Partners LLC purchased a new stake in iRadimed in the 2nd quarter valued at approximately $230,000. Finally, Legal & General Group Plc acquired a new position in iRadimed during the 2nd quarter worth approximately $639,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.